JP2007508291A - 皮脂産生を減少させるためのマロンアミド誘導体を含んでなる医薬組成物 - Google Patents
皮脂産生を減少させるためのマロンアミド誘導体を含んでなる医薬組成物 Download PDFInfo
- Publication number
- JP2007508291A JP2007508291A JP2006530738A JP2006530738A JP2007508291A JP 2007508291 A JP2007508291 A JP 2007508291A JP 2006530738 A JP2006530738 A JP 2006530738A JP 2006530738 A JP2006530738 A JP 2006530738A JP 2007508291 A JP2007508291 A JP 2007508291A
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- alkyl
- hydrogen
- compound
- methylethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pyridine Compounds (AREA)
Abstract
【解決手段】本発明は式Iにより記述されるマロンアミドACAT阻害剤の局所適用に関する。本発明の他の側面は、これらのジアミドの局所製剤、皮脂腺障害を治療するためのこれらの使用、そして油性肌を軽減するためのこれらの使用に関する。
【選択図】 なし
Description
特許請求の範囲を含み、本明細書を通して使用される以下の用語は、特に指示しない限り下に定義した意味を有する。複数及び単数は、数が指示される場合以外は相互交換的に取り扱うべきである:
a.「C1〜C6アルキル」とは、メチル、エチル、n−プロピル、イソプロピル、n−ブチル、イソブチル、n−ペンチル、イソペンチル、n−ヘキシル、1,1−ジメチルブチル、2,3−ジメチルブチルなどのような、1〜6の炭素原子を含む、分枝鎖又は直鎖アルキル基を指す。
a)N−ベンジル−N’−(2,6−ジイソプロピル−フェニル)−N−イソプロピル−マロンアミド;
b)N’−[2,6−ビス(1−メチルエチル)フェニル]−N−(1−メチルエチル)−N−[[4−(メチルチオ)フェニル]メチル]−プロパンジアミドそして;
c)N−[2,6−ビス(1−メチルエチル)フェニル]−]β−[[(4−メトキシフェニル)メチル](2−ピリジニル)アミノ]−]β−オキソ−プロパンアミド
が含まれる。
式Iの化合物は以前に、文献に記載されている。読者は、本明細書において援用される欧州特許出願第0 433 662号に注目されたい。‘662号の出願は、式Iの化合物がアシル−コエンザイムA コレステリルアシルトランスフェラーゼ(ACAT)阻害活性を有していることを開示している。‘662号の出願は、上昇したコレステロールレベルを低下させ、そしてアテローム性動脈硬化症を治療するために、これらの化合物が使用できることを開示している。‘662号の出願は、皮脂分泌を減少させるためにこれらの化合物を使用することは開示していない。
アシル−CoAコレステロールアシルトランスフェラーゼ(ACAT)の阻害は、遊離コレステロールからコレステロールエステルへのエステル化を阻止する。コレステロールエステルは、動物におけるコレステロールの主要な輸送及び保存形である。腸において、ACAT阻害剤は、腸管からのコレステロールの吸収を抑制することが示されている。肝臓において、ACATの阻害はリポタンパク質コアのコレステロールエステルの塊を減少させることにより、コレステロール含有リポタンパク質の形成及び分泌を減少させることが示されている。これらの理由により、ACAT阻害剤は血清コレステロールレベルを低下させるための手段として従来評価されてきた。
本発明の化合物は、多様な経路で投与することができる。経口で投与されたとしても有効である。化合物はまた、非経口的(即ち、皮下、静脈内、筋肉内、腹腔内又はクモ膜下腔内)、直腸的あるいは局所的に投与することもできる。
本発明のさらなる態様において、式Iの化合物は、それらの活性をさらに増強するため、あるいは潜在的副作用を最小にするため、他の化合物と同時投与することが可能である。例えば、テトラサイクリン及びクリンダマイシンのような抗生物質がアクネを軽減するために使用されてきた。抗生物質は微生物、プロピオンバクテリウム アクネス(Propionbacterium acnes)を根絶させ、患者のアクネの減少を導いている。式Iの化合物は、アクネの治療に適したいずれかの抗生物質と同時投与することが可能である。
もし望むなら、化合物をいずれの坦体も用いずに直接投与することが可能である。しかしながら、投与を容易にするため、それらは典型的には医薬坦体内へ配合されるであろう。
Luderschmidt らは、化合物が皮脂分泌を変調できるかどうかを試験するための動物モデルを記述している。Arch. Derm. Res. 258, 185-191 (1977) 。このモデルは、耳に皮脂腺を含有しているシリアンハムスターを使用する。試験剤が皮脂産生を変調可能かどうかを決定するため、化合物をこれらの動物へ投与できる。
Claims (15)
- 油性肌のための医薬品の製造における、式
- 前記化合物が、N−ベンジル−N’−(2,6−ジイソプロピル−フェニル)−N−イソプロピル−マロンアミド、N’−[2,6−ビス(1−メチルエチル)フェニル]−N−(1−メチルエチル)−N−[[4−(メチルチオ)フェニル]メチル]−プロパンジアミド、及びN−[2,6−ビス(1−メチルエチル)フェニル]−]β−[[(4−メトキシフェニル)メチル](2−ピリジニル)アミノ]−]β−オキソ−プロパンアミドから成る群より選択される、請求項1に記載の使用。
- 前記化合物が、N−ベンジル−N’−(2,6−ジイソプロピル−フェニル)−N−イソプロピル−マロンアミドである、請求項1に記載の使用。
- 局所医薬製剤であって、有効量の、式
- 前記化合物が、N−ベンジル−N’−(2,6−ジイソプロピル−フェニル)−N−イソプロピル−マロンアミド、N’−[2,6−ビス(1−メチルエチル)フェニル]−N−(1−メチルエチル)−N−[[4−(メチルチオ)フェニル]メチル]−プロパンジアミド、及びN−[2,6−ビス(1−メチルエチル)フェニル]−]β−[[(4−メトキシフェニル)メチル](2−ピリジニル)アミノ]−]β−オキソ−プロパンアミドから成る群より選択される、請求項6に記載の局所製剤。
- 前記化合物が、N−ベンジル−N’−(2,6−ジイソプロピル−フェニル)−N−イソプロピル−マロンアミドである、請求項6に記載の局所製剤。
- 皮脂分泌を減少させるための医薬品の製造における、式
- 前記化合物が、N−ベンジル−N’−(2,6−ジイソプロピル−フェニル)−N−イソプロピル−マロンアミド、N’−[2,6−ビス(1−メチルエチル)フェニル]−N−(1−メチルエチル)−N−[[4−(メチルチオ)フェニル]メチル]−プロパンジアミド、及びN−[2,6−ビス(1−メチルエチル)フェニル]−]β−[[(4−メトキシフェニル)メチル](2−ピリジニル)アミノ]−]β−オキソ−プロパンアミドから成る群より選択される、請求項7に記載の使用。
- 前記化合物が、N−ベンジル−N’−(2,6−ジイソプロピル−フェニル)−N−イソプロピル−マロンアミドである、請求項7に記載の使用。
- 皮脂腺障害のための医薬品の製造における、式
- 前記化合物が、N−ベンジル−N’−(2,6−ジイソプロピル−フェニル)−N−イソプロピル−マロンアミド、N’−[2,6−ビス(1−メチルエチル)フェニル]−N−(1−メチルエチル)−N−[[4−(メチルチオ)フェニル]メチル]−プロパンジアミド、及びN−[2,6−ビス(1−メチルエチル)フェニル]−]β−[[(4−メトキシフェニル)メチル](2−ピリジニル)アミノ]−]β−オキソ−プロパンアミドから成る群より選択される、請求項10に記載の使用。
- 前記化合物が、N−ベンジル−N’−(2,6−ジイソプロピル−フェニル)−N−イソプロピル−マロンアミドである、請求項10に記載の使用。
- 前記障害がアクネである、請求項10、11又は12のいずれかに記載の使用。
- 式
- 前記化合物が、N−ベンジル−N’−(2,6−ジイソプロピル−フェニル)−N−イソプロピル−マロンアミドである、請求項14に記載の物品。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50998403P | 2003-10-09 | 2003-10-09 | |
PCT/IB2004/003156 WO2005034931A1 (en) | 2003-10-09 | 2004-09-27 | Pharmaceutical compositions comprising malonamide derivatives for decreasing sebum production |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2007508291A true JP2007508291A (ja) | 2007-04-05 |
Family
ID=34435045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006530738A Ceased JP2007508291A (ja) | 2003-10-09 | 2004-09-27 | 皮脂産生を減少させるためのマロンアミド誘導体を含んでなる医薬組成物 |
Country Status (20)
Country | Link |
---|---|
US (3) | US7615230B2 (ja) |
EP (1) | EP1673077B1 (ja) |
JP (1) | JP2007508291A (ja) |
KR (1) | KR100786436B1 (ja) |
CN (1) | CN1863521B (ja) |
AR (1) | AR046176A1 (ja) |
AT (1) | ATE409470T1 (ja) |
AU (1) | AU2004280134B2 (ja) |
BR (1) | BRPI0415136A (ja) |
CA (1) | CA2541814C (ja) |
DE (1) | DE602004016874D1 (ja) |
DK (1) | DK1673077T3 (ja) |
ES (1) | ES2313065T3 (ja) |
IL (1) | IL174507A0 (ja) |
MX (1) | MXPA06003960A (ja) |
NO (1) | NO20061277L (ja) |
RU (1) | RU2342930C2 (ja) |
TW (1) | TWI286479B (ja) |
WO (1) | WO2005034931A1 (ja) |
ZA (1) | ZA200602840B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006232835A (ja) * | 2005-02-24 | 2006-09-07 | Warner-Lambert Co Llc | 結晶性acat阻害剤 |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE602004016874D1 (de) * | 2003-10-09 | 2008-11-13 | Warner Lambert Co | Pharmazeutische zusammensetzungen mit malonamid-derivaten zur verringerung der talg-produktion |
WO2006037468A1 (en) * | 2004-09-30 | 2006-04-13 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv reverse transcriptase inhibitors |
US20070142255A1 (en) * | 2005-12-16 | 2007-06-21 | Conopco, Inc., D/B/A Unilever | Skin benefit composition and a method for using the same |
EP2121579B1 (en) * | 2007-03-15 | 2011-04-20 | F. Hoffmann-La Roche AG | Malonamides as orexin antagonists |
US20080254074A1 (en) * | 2007-04-11 | 2008-10-16 | Conopco, Inc., D/B/A Unilever | Composition and method for regulating sebum flow |
FR2918890A1 (fr) * | 2007-07-19 | 2009-01-23 | Galderma Res & Dev | Utilisation du pactimibe pour la preparation d'un medicament destine a prevenir ou a traiter une maladie due a un dysfonctionnement des glandes sebacees chez l'homme ou l'animal |
FR2918889B1 (fr) * | 2007-07-19 | 2009-10-23 | Galderma Res & Dev | Utilisation de l'eflucimibe pour la preparation d'un medicament destine a prevenir ou a traiter une maladie due a un dysfonctionnement des glandes sebacees chez l'homme ou l'animal |
CN101502541B (zh) * | 2008-02-04 | 2011-12-28 | 成都地奥九泓制药厂 | 安息香属植物及其提取物的用途 |
FR2938342A1 (fr) * | 2008-11-13 | 2010-05-14 | Galderma Res & Dev | Ciblage de modulateurs de ces1 et/ou ces3 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee |
FR2946342B1 (fr) | 2009-06-05 | 2011-06-24 | Galderma Res & Dev | Nouveaux derives de dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
FR2946345B1 (fr) | 2009-06-05 | 2011-05-20 | Galderma Res & Dev | Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
FR2946340B1 (fr) | 2009-06-05 | 2011-06-24 | Galderma Res & Dev | Nouveaux n-phenyl acetamie, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
FR2946346B1 (fr) | 2009-06-05 | 2011-05-20 | Galderma Res & Dev | Nouveaux derives dioxo-imidazolidine, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant. |
WO2015048543A1 (en) * | 2013-09-26 | 2015-04-02 | Atterocor, Inc. | Treating disorders associated with aberrant adrenocortical cell behavior |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03220164A (ja) * | 1989-11-16 | 1991-09-27 | Warner Lambert Co | Acat阻害剤 |
JPH0899903A (ja) * | 1994-08-31 | 1996-04-16 | Pfizer Inc | 皮脂腺障害により引き起こされる疾患の治療法 |
JP2003104878A (ja) * | 2001-08-01 | 2003-04-09 | Warner Lambert Co Llc | 皮脂生産を阻害するためのワックス・エステルとコレステリル・エステル合成の2重阻害剤 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4299845A (en) * | 1980-04-14 | 1981-11-10 | Schering Corporation | Dermatological compositions and methods of use therefor |
DE4008501A1 (de) | 1989-12-18 | 1991-06-20 | Windmoeller & Hoelscher | Druckmaschine mit presseurs mit austauschbaren huelsenfoermigen presseurmaenteln |
US5362878A (en) * | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
GEP20043286B (en) | 2000-02-02 | 2004-07-26 | Warner Lambert Co | Dual Inhibitors of Cholesteryl Ester and Wax Ester Synthesis for Sebaceous Gland Disorders |
DE602004016874D1 (de) * | 2003-10-09 | 2008-11-13 | Warner Lambert Co | Pharmazeutische zusammensetzungen mit malonamid-derivaten zur verringerung der talg-produktion |
-
2004
- 2004-09-27 DE DE602004016874T patent/DE602004016874D1/de active Active
- 2004-09-27 AT AT04769499T patent/ATE409470T1/de not_active IP Right Cessation
- 2004-09-27 BR BRPI0415136-4A patent/BRPI0415136A/pt not_active IP Right Cessation
- 2004-09-27 CN CN2004800294673A patent/CN1863521B/zh not_active Expired - Fee Related
- 2004-09-27 WO PCT/IB2004/003156 patent/WO2005034931A1/en active IP Right Grant
- 2004-09-27 MX MXPA06003960A patent/MXPA06003960A/es active IP Right Grant
- 2004-09-27 JP JP2006530738A patent/JP2007508291A/ja not_active Ceased
- 2004-09-27 RU RU2006111458/15A patent/RU2342930C2/ru active
- 2004-09-27 CA CA2541814A patent/CA2541814C/en not_active Expired - Fee Related
- 2004-09-27 KR KR1020067006717A patent/KR100786436B1/ko not_active IP Right Cessation
- 2004-09-27 AU AU2004280134A patent/AU2004280134B2/en not_active Ceased
- 2004-09-27 DK DK04769499T patent/DK1673077T3/da active
- 2004-09-27 EP EP04769499A patent/EP1673077B1/en not_active Not-in-force
- 2004-09-27 ES ES04769499T patent/ES2313065T3/es active Active
- 2004-10-05 US US10/958,306 patent/US7615230B2/en not_active Expired - Fee Related
- 2004-10-07 TW TW093130426A patent/TWI286479B/zh not_active IP Right Cessation
- 2004-10-07 AR ARP040103633A patent/AR046176A1/es not_active Application Discontinuation
-
2006
- 2006-03-21 NO NO20061277A patent/NO20061277L/no not_active Application Discontinuation
- 2006-03-23 IL IL174507A patent/IL174507A0/en unknown
- 2006-04-06 ZA ZA200602840A patent/ZA200602840B/xx unknown
-
2009
- 2009-09-29 US US12/568,763 patent/US8409595B2/en not_active Expired - Fee Related
-
2013
- 2013-03-04 US US13/783,936 patent/US20130178446A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH03220164A (ja) * | 1989-11-16 | 1991-09-27 | Warner Lambert Co | Acat阻害剤 |
JPH0899903A (ja) * | 1994-08-31 | 1996-04-16 | Pfizer Inc | 皮脂腺障害により引き起こされる疾患の治療法 |
JP2003104878A (ja) * | 2001-08-01 | 2003-04-09 | Warner Lambert Co Llc | 皮脂生産を阻害するためのワックス・エステルとコレステリル・エステル合成の2重阻害剤 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006232835A (ja) * | 2005-02-24 | 2006-09-07 | Warner-Lambert Co Llc | 結晶性acat阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
ES2313065T3 (es) | 2009-03-01 |
DE602004016874D1 (de) | 2008-11-13 |
CA2541814A1 (en) | 2005-04-21 |
AR046176A1 (es) | 2005-11-30 |
RU2006111458A (ru) | 2007-10-27 |
NO20061277L (no) | 2006-06-29 |
EP1673077B1 (en) | 2008-10-01 |
BRPI0415136A (pt) | 2006-11-28 |
ATE409470T1 (de) | 2008-10-15 |
KR20060085658A (ko) | 2006-07-27 |
US20050079144A1 (en) | 2005-04-14 |
AU2004280134A1 (en) | 2005-04-21 |
CN1863521A (zh) | 2006-11-15 |
IL174507A0 (en) | 2006-08-01 |
TW200517137A (en) | 2005-06-01 |
US20130178446A1 (en) | 2013-07-11 |
US20100113601A1 (en) | 2010-05-06 |
WO2005034931A1 (en) | 2005-04-21 |
KR100786436B1 (ko) | 2007-12-17 |
US8409595B2 (en) | 2013-04-02 |
CA2541814C (en) | 2010-02-23 |
ZA200602840B (en) | 2007-09-26 |
US7615230B2 (en) | 2009-11-10 |
TWI286479B (en) | 2007-09-11 |
RU2342930C2 (ru) | 2009-01-10 |
EP1673077A1 (en) | 2006-06-28 |
AU2004280134B2 (en) | 2007-10-11 |
MXPA06003960A (es) | 2006-07-05 |
CN1863521B (zh) | 2012-01-25 |
DK1673077T3 (da) | 2008-12-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8409595B2 (en) | Method for decreasing sebum production | |
US8313782B2 (en) | Acne vulgaris treatment regimen | |
JP2003526595A (ja) | 細胞媒介性免疫病の処置 | |
JP2000515526A (ja) | Mtp阻害剤と他のコレステロール低下薬を組合せて使用する、血清脂質レベルの降下方法 | |
JP2022524780A (ja) | カンナビノイド酸エステル組成物およびその使用 | |
CN105017187A (zh) | 用于治疗皮肤病症或疾病状态的tofa类似物 | |
JP5925770B2 (ja) | ナイアシン模倣体、およびその使用方法 | |
US20080242729A1 (en) | Rxr Antagonists in the Treatment of Inflammatory Diseases | |
JP6343000B2 (ja) | オイゲノールを有効成分として含有するアトピー性皮膚炎の予防又は治療用組成物 | |
WO2017111069A1 (ja) | 止痒剤 | |
KR100802848B1 (ko) | 모발 성장 촉진 방법 | |
RU2457826C2 (ru) | Профилактическое или терапевтическое средство от алопеции | |
JP2009062316A (ja) | フラン脂肪酸乃至はその誘導体を含有する皮膚外用剤 | |
JP2014114234A (ja) | 皮膚外用剤 | |
HUT65945A (en) | Nonateraenoic acid derivaties and process for producing them | |
EP1429719B1 (fr) | Composition dermocosmetologique a visee anti-inflammatoire, en particulier pour le traitement de l'acne et de la dermite seborrhe que | |
CZ20021279A3 (cs) | Farmaceutické a/nebo kosmetické přípravky | |
RU2624238C2 (ru) | Лечение себореи | |
EP3500260A1 (en) | Glitazones for topical application | |
JP2011012025A (ja) | フルフェナジン及びイロプロスト類縁体を含んで成る発毛及び/又は養毛を促進するための組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070727 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20081216 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20081216 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20081225 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20091120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20091120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110315 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110323 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110406 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20110523 |
|
A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20110926 |